Prostate cancer is the most commonly diagnosed cancer in the UK. But screening is not universal, and charities are divided over whether it should be extended. What do those living with the disease ...

Although immunotherapy progress in prostate cancer has been slow, emerging strategies like bispecific T-cell engagers (BiTEs) show promise in overcoming historical resistance. In a recent discussion, ...

The European Randomized Study of Screening for Prostate Cancer (ERSPC) was initiated in 1993 to assess the effect of prostate-specific antigen (PSA) testing on prostate cancer mortality. Because ...

Leapman, MD, MHS, associate professor of urology at Yale University, addresses a critical and often overlooked limitation in the current landscape of prostate cancer biomarkers: while these tools have ...

Discusses First Clinical Outcomes and Precision of TULSA from the CAPTAIN Trial in Prostate Cancer March 13, 2026 11:30 ...

Screening with the prostate-specific antigen (PSA) test can detect early-stage prostate cancer while it's still asymptomatic. But some men are diagnosed with prostate cancer only after symptoms appear ...